Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1
Xiao‐Yu Liu, Ni Zhang, Sheng‐Xiao Zhang, Ping Xu
Abstract
Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon-like peptide-1 (GLP-1), a gut incretin hormone, has become a well-established treatment for T2DM and is likely to be involved in treating cognitive impairment. In this mini review, the similarities between AD and T2DM are summarised with the main focus on GLP-1-based therapeutics in AD.
Topics & Concepts
IncretinType 2 Diabetes MellitusDiseaseGlucagon-like peptide-1Cognitive impairmentAlzheimer's diseaseMedicineType 2 diabetesNeuroscienceHormoneDiabetes mellitusBioinformaticsInternal medicineEndocrinologyPsychologyBiologyDiabetes Treatment and ManagementNeuropeptides and Animal PhysiologyPancreatic function and diabetes